cytarabine has been researched along with Leukemia, Smoldering in 79 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (22.78) | 18.7374 |
| 1990's | 25 (31.65) | 18.2507 |
| 2000's | 25 (31.65) | 29.6817 |
| 2010's | 9 (11.39) | 24.3611 |
| 2020's | 2 (2.53) | 2.80 |
| Authors | Studies |
|---|---|
| Li, TT; Ran, XH; Sun, L; Wang, LJ; Wu, XF | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M | 1 |
| Fernández-Sojo, J; Oliveras Vilà, T; Ribera, JM; Vives, S | 1 |
| Hu, C; Jin, J; Lin, P; Lou, Y; Luo, Y; Ma, L; Mai, W; Mei, C; Meng, H; Qian, J; Qian, W; Ren, Y; Tong, H; Wei, J; Xie, L; Xu, G; Xu, W; Ye, L; Ye, X; Zhou, X | 1 |
| Hackanson, B; Lübbert, M; Rückert, A | 1 |
| Alvaro, MG; Baraldi, A; Ciravegna, G; Corsetti, MT; De Paoli, L; Gatto, S; Levis, A; Perticone, S; Pietrasanta, D; Pini, M; Primon, V; Salvi, F; Tonso, A; Zallio, F | 1 |
| Kuendgen, A | 1 |
| Chae, YS; Kang, BW; Kim, JG; Lee, SJ; Lee, YJ; Moon, JH; Sohn, SK; Suh, JS | 1 |
| Baro, J; Bermúdez, A; Colorado, M; Conde, E; Díez-Gallarreta, Z; Gutiérrez, ML; Insunza, A; Iriondo, A; López-Duarte, M; Olalla, I; Pérez-Vázquez, G; Richard, C; Sanroma, P; Yañez, L | 1 |
| Ades, L; Berger, E; Bordessoule, D; Braun, T; Cahn, JY; Charbonnier, A; Chaury, MP; Cheze, S; Dreyfus, F; Etienne, G; Fenaux, P; Guerci-Bresler, A; Legros, L; Natarajan-Amé, S; Park, S; Ravoet, C; Schmidt, A; Stamatoullas, A; Vey, N | 1 |
| Hamamoto, K; Hasegawa, D; Kikuchi, A; Kojima, S; Manabe, A; Nakahata, T; Ohtsuka, Y; Okamura, J | 1 |
| Cortes, J; Davis, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; O'Brien, S; Thomas, D | 1 |
| Antoun, S; Carpiuc, I; Delabarthe, A; Driss, B; Fenaux, R; Griscelli, F; Ribrag, V; Vantelon, JM | 1 |
| Breitenbuecher, F; Fischer, T; Gamm, H; Gschaidmeier, H; Hess, G; Huber, C; Kindler, T; Kirkpatrick, CJ; Marx, A | 1 |
| Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Thomas, D; Tsimberidou, A; Verstovsek, S | 1 |
| Bernell, P; Björkholm, M; Celsing, F; Dahl, IM; Dybedal, I; Gahrton, G; Hast, R; Hellström-Lindberg, E; Lerner, R; Lindberg, G; Linder, O; Löfvenberg, E; Nilsson-Ehle, H; Oberg, G; Ohm, L; Paul, C; Samuelsson, J; Tangen, JM; Tidefelt, U; Turesson, I; Wahlin, A; Wallvik, J; Winquist, I | 1 |
| Bergmann, L; Fischer, JT; Ganser, A; Heil, G; Hoeffken, K; Hoelzer, D; Hofmann, WK; Knuth, A; Koelbel, CB; Kolbe, K; Langer, W; Ottmann, OG; Schmoll, HJ; Westerhausen, M; Wiebe, S; Zander, C | 1 |
| Addamo, B; Benner, A; Biedermann, HG; del Valle, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Glasmacher, A; Götze, K; Griesinger, F; Grimminger, W; Haas, R; Hartmann, F; Hensel, M; Kirchen, H; Koller, E; Kremers, S; Mergenthaler, HG; Pralle, H; Preiss, J; Salwender, H; Schlenk, RF; Schoch, R; Waterhouse, C | 1 |
| Cubitt, D; Dignan, F; Khot, A; Potter, M; Taylor, S; Treleaven, JG | 1 |
| Conte, ML; Indolfi, P; La Manna, A; Locatelli, F; Nobili, B; Perrotta, S; Rossi, F | 1 |
| Bonaccorso, R; Citarrella, P; Ciulla, A; Di Marco, P; Di Salvo, V; Gebbia, V; Mansueto, S; Tambone Reyes, M; Tinnirello, D | 1 |
| Califano, C; Celentano, M; D'Amico, MR; D'Arco, AM; Ferrara, F; Mele, G; Palmieri, S; Pollio, F | 1 |
| Ashida, T; Higashishiba, M; Kanamaru, A; Kawanishi, K; Mayama, T; Miyatake, J; Tatsumi, Y | 1 |
| Nakamura, T; Sakamaki, I; Sudou, H; Ueda, T; Wano, Y; Wataya, S | 1 |
| Boogaerts, MA; Delforge, M; Demuynck, H; Marijnen, P; Van den Berghe, H; van Duppen, V; Vandenberghe, P; Verhoef, G; Zachée, P | 1 |
| Anastasi, J; Hayashi, Y; McGavran, L; Nucifora, G; Roulston, D; Rowley, JD; Rudinsky, R; Tsuchida, M; Zeleznik-Le, N | 1 |
| Fujii, H; Kuzuyama, Y; Nakagawa, H; Sonoda, Y | 1 |
| Mehta, J; Philpott, N; Powles, R; Treleaven, J | 1 |
| Brianzoni, F; Centurioni, R; Ciniero, L; Danieli, G; Leoni, P; Montillo, M; Offidani, M; Olivieri, A; Salvi, A; Ziarati, H | 1 |
| Kobayashi, Y; Kondo, M; Maruo, N; Ozawa, M | 1 |
| Jowitt, SN; Yin, JA | 1 |
| Chaibi, P; de Revel, T; Dombret, H; Gardin, C; Micléa, JM; Nédellec, G; Rousselot, P; Turlure, P | 1 |
| Goldberg, SL; Klumpp, TR; Mangan, KF; Ming, PL; Mullaney, MT; Rao, PN; Redei, I | 1 |
| Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S | 1 |
| Bender-Götze, C; Creutzig, U; Körholz, D; Niemeyer, C; Ritter, J; Stollmann-Gibbels, B; Zimmermann, M | 1 |
| Itoh, R; Mizuno, T; Morita, K; Suzuki, H; Tanaka, I | 1 |
| Abgrall, JP; Brice, P; Brion, A; Caillot, D; Cordonnier, C; Desablens, B; Dreyfus, F; Fenaux, P; Gratecos, N; Guerci, A; Hecquet, B; Hoang-Ngoc, L; Ifrah, N; Janvier, M; Leporrier, M; Lioure, B; Milpied, N; Pignon, B; Rochant, H; Sadoun, A; Solary, E; Stoppa, AM; Tilly, H; Veil, A; Wattel, E | 1 |
| Andreeff, M; Beran, M; Cortes, J; Estey, E; Giles, FJ; Hayes, K; Kantarjian, H; Keating, M; Koller, CA; Kornblau, S; O'Brien, S; Pierce, SR; Vey, N; Wong, GC | 1 |
| Aoyagi, A; Aoyagi, M; Arai, H; Arai, Y; Furusawa, S; Gunnji, H; Handa, T; Inoue, F; Kawagoe, Y; Kitsukawa, Y; Nakamura, Y; Saito, K; Tadokoro, J; Takahashi, W; Tsurumi, S; Waga, K; Yamamoto, K | 1 |
| Chiba, K; Fukuhara, T; Hirano, T; Kakinoki, Y; Kurosawa, M; Maekawa, I; Miyake, T; Mori, A; Morioka, M; Noto, S; Okabe, M; Suzuki, S; Toyoshima, T; Tsutsumi, Y | 1 |
| Lorsbach, RB; Mathew, S; Raimondi, SC; Sandlund, JT; Shearer, P | 1 |
| Gáliková, J; Haas, T; Lemez, P | 1 |
| Dohi, K; Fujimoto, S; Nakamura, S; Nakatani, K; Nishino, T; Shiiki, H | 1 |
| Brookes, J; Carey, P; Chu, P; Deane, M; Duncombe, A; Ganly, PS; Hutchinson, M; Jackson, G; Johnson, SA; Littlewood, TJ; MacKie, MJ; Marcus, R; Mehta, AB; Schey, S; Smith, A; Smith, GM; Taylor, P; Tollerfield, SM; Turner, GE; Wilson, MP | 1 |
| Bennett, JM; Dewald, GW; Friedenberg, WR; Hayes, FA; Hiddemann, W; Lazarus, HM; Liesveld, JL; Marsh, RD; Miller, KB; Paietta, E; Rowe, JM; Saba, HT; Young, MS | 1 |
| Bardy, P; Horvath, N; Hughes, T; Hui, CH; To, LB | 1 |
| Abe, T; Arai, Y; Gotoh, S; Ishikawa, T; Kakazu, N; Matsushita, A; Nagai, K; Ohki, M; Ohno, T; Shinzato, I; Takahashi, T; Tsuchiya, T | 1 |
| Aoki, S; Imai, K; Kazama, Y; Shimizu, H; Takahashi, T; Tsujisaki, M; Yoshimoto, M | 1 |
| Craddock, C; Garg, M; Lawler, M; Pawson, R; Potter, MN; Prentice, HG; Rassam, S; Rezvani, K; Theocharous, P; Yin, JA | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; O'Brien, S; Pierce, SA; Thall, PF; Wang, X | 1 |
| Alimena, G; Breccia, M; Carmosino, I; D'Andrea, M; D'Elia, GM; Petti, MC | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; Pierce, SA; Thall, PF; Thomas, DA; Wang, XM | 1 |
| Asano, S; Ikebuchi, K; Irie, S; Ogura, H; Okamoto, S; Ozawa, K; Satoh, N; Tani, K; Tojo, A | 1 |
| Bennett, JM; Cassileth, PA; Head, DR; Kim, K; Kyungmann, K; Miller, KB; Morrison, FS; Neiman, RS; O'Connell, MJ; Winter, JN | 1 |
| de Witte, T; Delmer, A; Fiere, D; Gerhartz, HH; Jacobs, A; Labar, B; Marcus, R; Sonneveld, P; Visiani, G; Zwierzina, H | 1 |
| Chen, YC; Lin, MT; Liu, MC; Lui, LT; Tang, JL; Wang, CH | 1 |
| Hironaka, T; Horiike, S; Kashima, K; Misawa, S; Nakagawa, H; Nishigaki, H; Shizumi, Y; Takashima, T; Tanaka, S; Taniwaki, M | 1 |
| Bauters, F; Fenaux, P; Jouet, JP; Lai, JL; Morel, P; Rose, C | 1 |
| Denzlinger, C; Gerhartz, HH; Grimberg, M; Kapp, A; Wilmanns, W | 1 |
| Gattringer, C; Konwalinka, G; Linkesch, W; Thaler, J | 1 |
| Hölzel, D; Nüssler, V; Pelka-Fleischer, R; Sauer, H; Wilmanns, W | 1 |
| Chomienne, C; Degos, L; Najean, Y; Thomas, G | 1 |
| Brito-Babapulle, F; Lord, JA; Whitmore, DN | 1 |
| Hoshino, A; Ito, T; Kamiya, O; Nagata, K; Ohara, K; Ono, Y; Saito, M; Yamamoto, K | 1 |
| Dan, K; Kuriya, S; Nomura, T; Shiomura, T; Sueoka, N; Tanabe, Y; Yamada, T | 1 |
| Ichimaru, M; Jinnai, I; Kohno, T; Nagai, K; Tagawa, M; Tomonaga, M; Tsukazaki, K | 1 |
| Arthur, DC; Brunning, RD; Michels, SD; Robison, LL; Saumur, J | 1 |
| Champlin, RE; Gajewski, JL; Gekelman, L; Hirji, KF; Ho, WG; Jacobs, AD; Nimer, SD | 1 |
| Miyazaki, T; Morioka, M; Sakurada, K | 1 |
| Bayle, J; Cassuto, JP; Dujardin, P; Fuzibet, JG; Gratecos, N; Pesce, A; Raynaud, S | 1 |
| Abita, JP; Castaigne, S; Chomienne, C; Degos, L; Najean, Y; Poirier, O | 1 |
| Bancillon, A; Castaigne, S; Daniel, MT; Leverger, G; Schaison, G; Valensi, F | 1 |
| Fridrik, MA; Herbinger, W; Wahl, G | 1 |
| Furukawa, Y; Inoue, T; Kishida, T; Kojima, K; Sagawa, H; Sannomiya, Y; Sasaki, A; Yamane, T; Yokomatsu, Y; Yoshikawa, T | 1 |
| Dohy, H; Kyo, T | 2 |
| Cantù-Rajnoldi, A; Conter, V; Creutzig, U; Masera, G; Odenwald, E; Riehm, H; Ritter, J; Romitti, L | 1 |
| Arimori, S; Kubota, T; Nagao, T; Noguchi, K; Oobayashi, Y; Satou, Y; Yonekura, S | 1 |
5 review(s) available for cytarabine and Leukemia, Smoldering
| Article | Year |
|---|---|
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML).
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Disease Progression; Fatal Outcome; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukocytosis; Male; Monosomy; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic | 2009 |
Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Lineage; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Enzyme Inhibitors; Etoposide; Fatal Outcome; Female; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Mitoxantrone; Neoplasms, Second Primary; Oncogenes; Topoisomerase II Inhibitors; Translocation, Genetic | 1995 |
[Differentiating agents in myelodysplastic syndromes. Analysis of personal cases].
Topics: Aged; Anemia, Myelophthisic; Anemia, Refractory, with Excess of Blasts; Colony-Stimulating Factors; Cytarabine; Female; Humans; Leukemia, Myelomonocytic, Acute; Leukemia, Myelomonocytic, Chronic; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Myelodysplastic Syndromes | 1993 |
Acute erythroleukemia with t(3;5) accompanied by hepatocellular carcinoma.
Topics: Aclarubicin; Adolescent; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Carcinoma, Hepatocellular; Child; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 5; Cytarabine; Daunorubicin; Doxorubicin; Female; Hepatectomy; Hepatitis B; Humans; Leukemia, Erythroblastic, Acute; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Prednisolone; Remission Induction; Translocation, Genetic | 1991 |
20 trial(s) available for cytarabine and Leukemia, Smoldering
| Article | Year |
|---|---|
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Anticonvulsants; Antimetabolites, Antineoplastic; Cytarabine; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Treatment Outcome; Valproic Acid | 2011 |
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyrazines; Survival Analysis; Treatment Outcome | 2012 |
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Topics: Adult; Amifostine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome | 2002 |
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Alanine Transaminase; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival; Treatment Outcome; Vidarabine | 2003 |
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Survival Rate; Thioguanine | 2003 |
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Survival Rate; Treatment Outcome | 2004 |
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous; Tretinoin | 2004 |
Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marrow Diseases; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Neoplasms; Prospective Studies; Radiotherapy; Remission Induction; Salvage Therapy; Treatment Outcome | 1994 |
Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Réflexion en Hématologie.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Prospective Studies; Remission Induction | 1997 |
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Cytarabine; Disease Progression; Female; Genes, MDR; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Phenotype; Quinine; Remission Induction; Survival Analysis | 1999 |
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Prognosis; Remission Induction; Topotecan | 1999 |
Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Survival Rate; Treatment Outcome | 2000 |
A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Recurrence; Vidarabine | 2001 |
Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chemical and Drug Induced Liver Injury; Cytarabine; DNA Replication; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hyperbilirubinemia; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Pancytopenia; Pilot Projects; Recombinant Proteins; Remission Induction; S Phase; Treatment Failure | 2001 |
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction; Survival Rate; Time Factors; Topotecan; Treatment Failure; Vidarabine | 2001 |
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Topics: Acute Disease; Aged; Aged, 80 and over; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Cytarabine; Drug Therapy, Combination; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Infusions, Parenteral; Interleukin-11; Leukemia, Myeloid; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Therapeutic Equivalency | 2002 |
The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Blood Transfusion; Cytarabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 1992 |
Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Leukemia; Male; Middle Aged; Risk Factors; Survival Rate | 1992 |
Enhanced endogenous leukotriene biosynthesis in patients treated with granulocyte-macrophage colony-stimulating factor.
Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Chromatography, High Pressure Liquid; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukocyte Count; Leukotrienes; Male; Middle Aged; Radioimmunoassay | 1990 |
[Refractory anemia with partial blastosis. A new therapeutic approach].
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Cholecalciferol; Clinical Trials as Topic; Colony-Stimulating Factors; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Interferons; Isotretinoin; Prognosis; Remission Induction | 1989 |
54 other study(ies) available for cytarabine and Leukemia, Smoldering
| Article | Year |
|---|---|
[Clinical Comparation of Two Kinds of Chemotherapy Regimens in the Treatment of Patients with MDS-RAEB/AML-MRC].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2020 |
[Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2017 |
[Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Azacitidine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Hepatomegaly; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Serositis | 2014 |
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.
Topics: Aclarubicin; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Karyotype; Male; Middle Aged; Mutation; Retrospective Studies | 2017 |
An inexpensive way to treat elderly patients with high-risk MDS or AML.
Topics: Anemia, Refractory, with Excess of Blasts; Anticonvulsants; Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Treatment Outcome; Valproic Acid | 2011 |
Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Disease Progression; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pilot Projects; Treatment Outcome | 2012 |
FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Treatment Outcome; Vidarabine | 2012 |
Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Child; Cytarabine; Etoposide; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Mitoxantrone; Remission Induction; Treatment Outcome | 2012 |
Segmental coecal cytomegalovirus colitis during fludarabine, cytarabine and mitoxantrone induction chemotherapy for myelodysplastic syndrome.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cecal Diseases; Colitis; Cytarabine; Cytomegalovirus Infections; Female; Humans; Middle Aged; Mitoxantrone; Vidarabine | 2002 |
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Remission Induction; Salvage Therapy | 2003 |
Another case of PORN (bilateral progressive outer retinal necrosis) after allogeneic stem cell transplantation.
Topics: Acyclovir; Administration, Oral; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cytarabine; DNA, Viral; Eye Infections, Viral; Granulocyte Colony-Stimulating Factor; Herpesvirus 3, Human; Humans; Male; Middle Aged; Retinitis; Stem Cell Transplantation; Transplantation, Homologous; Valacyclovir; Valine; Vidarabine | 2006 |
Membranous glomerulopathy in children given allogeneic hematopoietic stem cell transplantation.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Edema; Glomerulonephritis, Membranous; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Male; Mercaptopurine; Methotrexate; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vincristine | 2005 |
Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 1989 |
An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Remission Induction; Stem Cell Transplantation; Vidarabine | 2006 |
Successful reduced-intensity stem cell transplantation in a patient with myelodysplastic syndrome combined with Sweet's syndrome.
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Anti-Inflammatory Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Graft vs Host Disease; Humans; Male; Middle Aged; Prednisolone; Remission Induction; Sweet Syndrome; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
[Successful treatment of a 74-year-old man with refractory anemia with excess of blasts in transformation (RAEB in T) by low-dose Ara-C injection].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Cytarabine; Humans; Injections, Subcutaneous; Male; Remission Induction | 1995 |
Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antigens, CD; Antigens, CD34; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Marrow; Cell Separation; Cell Transformation, Neoplastic; Clone Cells; Colony-Forming Units Assay; Cytarabine; Dosage Compensation, Genetic; Feasibility Studies; Female; Filgrastim; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lenograstim; Middle Aged; Mitoxantrone; Molecular Sequence Data; Recombinant Proteins; Risk; Sialic Acid Binding Ig-like Lectin 3 | 1995 |
[Peripheral blood stem cell transfusion for a patient with RAEB-T].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Remission Induction; Stem Cell Transplantation | 1993 |
Megakaryocytic ploidy in myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Azure Stains; Biomarkers; Cytarabine; DNA; Female; Flow Cytometry; Humans; Indoles; Male; Megakaryocytes; Middle Aged; Myelodysplastic Syndromes; Ploidies; Polyploidy; Remission Induction | 1993 |
Clonality switch in acute myeloid leukemia.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Clone Cells; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Dosage Compensation, Genetic; Female; Hematopoiesis; Heterozygote; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Prednisolone; Remission Induction; Thioguanine; Vincristine | 1996 |
Detection of a dormant 20q- leukemia clone in bone marrow cultures with hematopoietic growth factors: implications for secondary leukemia post-transplant.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Chromosome Deletion; Chromosomes, Human, Pair 20; Clone Cells; Combined Modality Therapy; Cytarabine; Dacarbazine; Doxorubicin; Female; Hematopoietic Cell Growth Factors; Hodgkin Disease; Humans; Mechlorethamine; Neoplasm, Residual; Neoplasms, Second Primary; Neoplastic Stem Cells; Prednisone; Procarbazine; Radiotherapy; Recurrence; Transplantation, Autologous; Vinblastine; Vincristine | 1997 |
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine | 1995 |
The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t.
Topics: Adolescent; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Transformation, Neoplastic; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Male; Mitoxantrone; Remission Induction | 1998 |
[Successful emergency operation for massive hemorrhage due to jejunal angiodysplasia after intensive chemotherapy in a patient with refractory anemia with excess of blasts].
Topics: Anemia, Refractory, with Excess of Blasts; Angiodysplasia; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Therapy, Combination; Emergencies; Enterocolitis; Gastrointestinal Hemorrhage; Humans; Idarubicin; Jejunal Diseases; Male; Mercaptopurine; Middle Aged; Neutropenia; Prednisolone; Vincristine | 1998 |
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Lymphocyte Activation; Male; Neoplasms, Second Primary; Survival Rate; Treatment Outcome | 2000 |
Double minute chromosomes and c-MYC amplification in a child with secondary myelodysplastic syndrome after treatment for acute lymphoblastic leukemia.
Topics: Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Chromosome Aberrations; Chromosomes, Human, Pair 8; Cladribine; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Fatal Outcome; Female; Gene Amplification; Genes, myc; Humans; Hydrocortisone; Karyotyping; Mercaptopurine; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Vincristine | 2000 |
[Poor response in patients with de novo acute myeloid leukemia and erythroblastic or megakaryocytic dysplasia to treatment with standard doses of cytosine arabinoside and daunorubicin].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Erythroblasts; Humans; Leukemia, Myeloid; Megakaryocytes; Middle Aged | 1999 |
Cytosine arabinoside induced acute interstitial nephritis in a patient treated for refractory anemia with excess of blasts in transformation.
Topics: Acute Disease; Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Nephritis, Interstitial | 2000 |
Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Recombinant Proteins; Recurrence; Salvage Therapy; Transplantation, Homologous; Vidarabine | 2001 |
Involvement of the NUP98 gene in a chromosomal translocation t(11;20)(p15;q11.2) in a patient with acute monocytic leukemia (FAB-M5b).
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 20; Combined Modality Therapy; Cytarabine; Disease Progression; Fatal Outcome; Female; Hemorrhage; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Monocytic, Acute; Mercaptopurine; Middle Aged; Neoplasm Proteins; Nuclear Pore Complex Proteins; Prednisolone; Sepsis; Translocation, Genetic | 2001 |
Myelodysplastic syndrome progresses rapidly into erythroleukemia associated with synchronous double cancers of the stomach and the papilla of Vater.
Topics: Aclarubicin; Adenocarcinoma; Aged; Ampulla of Vater; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cholestasis, Extrahepatic; Chromosome Aberrations; Chromosome Disorders; Common Bile Duct Neoplasms; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Karyotyping; Leukemia, Erythroblastic, Acute; Male; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Pancytopenia; Stomach Neoplasms | 2001 |
Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Filgrastim; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Recurrence; Reoperation; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Contraindications; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Neoplasms, Second Primary; Remission Induction; Skin Neoplasms; Vidarabine | 2002 |
Case report: alternation therapy with antileukemic agents and recombinant human granulocyte colony-stimulating factor for RAEB in transformation.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged | 1992 |
Successful reinduction of remission with low-dose Ara-C in a patient with myelodysplastic syndrome relapsed after allogeneic bone marrow transplantation: restoration of donor hematopoiesis detected by amplification of minisatellite genes.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Base Sequence; Bone Marrow Transplantation; Cytarabine; DNA Fingerprinting; Female; Genes, ras; Hematopoiesis; Humans; Molecular Sequence Data; Oligonucleotides; Polymerase Chain Reaction | 1992 |
Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.
Topics: Adolescent; Adult; Aged; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antibiotics, Antineoplastic; Cytarabine; Drug Therapy, Combination; Female; Humans; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Prognosis; Remission Induction | 1991 |
Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Austria; Blast Crisis; Cytarabine; Drug Evaluation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1990 |
Clinical, biochemical and cytokinetic parameters for distinguishing smouldering and rapidly proliferating variants of acute leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cytarabine; DNA; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thymidine Kinase | 1990 |
Treatment of RAEB-t with intensive chemotherapy and GM-CSF.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Transformation, Neoplastic; Colony-Stimulating Factors; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Middle Aged; Mitoxantrone | 1989 |
[A case of RAEB in transformation successfully treated by low-dose Ara-C treatment].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Cytarabine; Humans; Male | 1989 |
[RAEB in transformation in continuing complete remission by small doses of cytarabin].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Cytarabine; Female; Humans; Male; Middle Aged | 1989 |
[Effects of low dose Ara-C regimen in acute leukemias and RAEB].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Cytarabine; Drug Evaluation; Female; Humans; Leukemia; Male; Middle Aged; Remission Induction | 1989 |
Refractory anemia with excess of blasts in transformation hematologic and clinical study of 52 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Bone Marrow Transplantation; Chromosome Aberrations; Chromosome Disorders; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Female; Humans; Karyotyping; Male; Middle Aged; Remission Induction | 1989 |
Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome.
Topics: Age Factors; Anemia, Aplastic; Anemia, Refractory, with Excess of Blasts; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Multivariate Analysis; Neural Tube Defects; Preleukemia; Prognosis; Regression Analysis; Survival Rate; Thioguanine | 1989 |
[Therapy of the preleukemic state: effect of androgens on refractory anemia].
Topics: Adult; Aged; Androgens; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Blast Crisis; Cholecalciferol; Chromosome Aberrations; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Preleukemia; Prognosis | 1988 |
Very-low-dose cytarabine for elderly patients.
Topics: Adult; Age Factors; Aged; Anemia, Refractory, with Excess of Blasts; Cytarabine; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1986 |
Pharmacokinetic data on very-low-dose cytarabine.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Cytarabine; Drug Administration Schedule; Humans; Kinetics | 1986 |
[Efficacy of low-dose cytarabine after failure of conventional chemotherapy].
Topics: Anemia, Refractory, with Excess of Blasts; Child; Cytarabine; Female; Humans | 1985 |
Low dose cytosine arabinoside in refractory anemia with excess of blasts in transformation.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Bacterial Infections; Bone Marrow; Cell Transformation, Neoplastic; Cytarabine; Drug Administration Schedule; Female; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Remission Induction | 1988 |
[Differentiating effect of the oral administration of vitamin D and vitamin A in acute myelocytic leukemia after BHAC-DMP therapy].
Topics: Administration, Oral; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Vitamin A; Vitamin D | 1988 |
Results of aggressive chemotherapy for myelodysplastic syndromes.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Remission Induction; Vincristine | 1988 |
[Intensive chemotherapy of refractory anemia with excess of blasts].
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Infusions, Intravenous; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Remission Induction; Vincristine | 1988 |
Myelodysplastic syndromes in childhood. Report of 21 patients from Italy and West Germany.
Topics: Adolescent; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chromosome Aberrations; Cytarabine; Female; Germany, West; Humans; Infant; Italy; Male; Myelodysplastic Syndromes | 1987 |
Small-dose cytosine arabinoside in the treatment of elderly patients with acute leukemia and refractory anemia with excess of blast.
Topics: Acute Disease; Aged; Anemia, Refractory, with Excess of Blasts; Bone Marrow Diseases; Cytarabine; Humans; Infections; Injections, Subcutaneous; Leukemia; Male; Middle Aged; Nausea | 1986 |